Search Results 511-520 of 17715 for SC

  1. A Study Of Amivantamab In Combination With Lazertinib, Or Amivantamab In Combination With Platinum-Based Chemotherapy, For Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced Or Metastatic Non-Small Cell Lung Cancer (NSCLC) - Mayo Clinic

    About this study. The primary purpose of the study is to assess how well amivantamab subcutaneous (SC) administration in combination with lazertinib or in ...

  2. Publications - Adam L. Holtzman, M.D. - Mayo Clinic

    Olson B, Bogan A, Abdel-Halim CN, Rolle-McFarland D, Graves J, Vallecillo T, Ma DJ, Neben-Wittich MA, Lester SC, Gamez M, Holtzmann A, Mohammadi H, Garcia J ...

  3. Inclisiran For Participants With Atherosclerotic Cardiovascular Disease And Elevated Low-density Lipoprotein Cholesterol - Mayo Clinic

    ... (SC) inclisiran injection(s). The study will be a multicenter study in the United States. Participation eligibility. Participant eligibility includes age ...

  4. Gastroenterology and Hepatology - Clinical trials

    The purpose of this study is to assess the pharmacodynamics (PD) of HM15211 after administration of multiple subcutaneous (SC) doses compared to placebo on ...

  5. Shaheen S. Kurani - Training and Education - Center for Clinical and Translational Science (CCaTS)

    Anthropology and Human Biology, Emory University; Sc.M., Public Health and Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public ...

  6. Publications - Chris M. Adams, M.D., Ph.D. - Mayo Clinic

    ... SC, Bround MJ, Sargent MA, Adams CM, Molkentin JD. Thbs1 regulates skeletal muscle mass in a TGFbeta-Smad2/3-ATF4-dependent manner. Cell Rep. 2024 May 28 ...

  7. Randal J. Thomas, M.D. - Doctors and Medical Staff - Mayo Clinic

    ... South Carolina. Areas of clinical expertise include: Management of patients with risk factors for cardiovascular disease; Management of patients with ...

  8. Publications - Nicholas L. Deep, M.D. - Mayo Clinic

    2025 Jan; 47(1):1-7. Marinelli JP, Rahne T, Dornhoffer JR, Lohse CM, Cottrell J, Thomas Roland J Jr, Thompson NJ, Brown KD, Lucas JC, Babu SC, Lindquist NR ...

  9. A Phase 3 Study To Examine The Effectiveness, Safety And Tolerability Of APL-130277 For The Acute Treatment Of Motor Fluctuation Episodes In Patients With Parkinson's Disease - Mayo Clinic

    continuous s.c. apomorphine infusion; or Duodopa/Duopa. Treatment with any form of s.c. apomorphine within 7 days prior to the initial screening visit (SV1).

  10. Morphine (injection route) - Side effects & uses - Mayo Clinic

    Morphine injection is used to treat pain severe enough to require opioid treatment and when other pain medicines did not work well enough or cannot be tolerated ...